β-Catenin loss in hepatocytes promotes hepatocellular cancer after diethylnitrosamine and phenobarbital administration to mice

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Awuah, Prince Kwaku ^a   Rhieu, Byung Han ^a   Singh, Sucha ^a   Misse, Amalea ^a   Monga, Satdarshan P S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; DIETHYLNITROSAMINE; GLUTAMATE AMMONIA LIGASE; PHENOBARBITAL; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL ACTIVATION; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENZYME REPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER REGENERATION; MALE; MOUSE; NONHUMAN; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STELLATE CELL; TISSUE LEVEL; TUMOR VOLUME;

ANIMALS; BETA CATENIN; CARCINOGENS; DIETHYLNITROSAMINE; HEPATOCYTES; IMMUNOHISTOCHEMISTRY; LIGANDS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOBARBITAL; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 84862687896     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039771     Document Type: Article

References (41)

1. Parkin DM, (2001) Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543.
2. Lustig B, Behrens J, (2003) The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 129: 199-221.
3. Clevers H, (2006) Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480.
4. Peifer M, Polakis P, (2000) Wnt signaling in oncogenesis and embryogenesis-a look outside the nucleus. Science 287: 1606-1609.
5. Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, et al. (2003) Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 423: 448-452.
6. Nelson WJ, Nusse R, (2004) Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303: 1483-1487.
7. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, et al. (1998) Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 95: 8847-8851.
8. Wong CM, Fan ST, Ng IO, (2001) beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 92: 136-145.
9. Kalinichenko VV, Major ML, Wang X, Petrovic V, Kuechle J, et al. (2004) Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev 18: 830-850.
10. Matsumoto K, Huang J, Viswakarma N, Bai L, Jia Y, et al. (2010) Transcription coactivator PBP/MED1-deficient hepatocytes are not susceptible to diethylnitrosamine-induced hepatocarcinogenesis in the mouse. Carcinogenesis 31: 318-325.
11. Kudo M, (2011) Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. Dig Dis 29: 289-302.
12. Oseini AM, Roberts LR, (2009) PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma? Expert Opin Ther Targets 13: 443-454.
13. Stock P, Monga D, Tan X, Micsenyi A, Loizos N, et al. (2007) Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther 6: 1932-1941.
14. Zhang T, Sun HC, Xu Y, Zhang KZ, Wang L, et al. (2005) Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin Cancer Res 11: 8557-8563.
15. Aydinlik H, Nguyen TD, Moennikes O, Buchmann A, Schwarz M, (2001) Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of beta-catenin-mutated mouse liver tumors. Oncogene 20: 7812-7816.
16. Ogawa K, Yamada Y, Kishibe K, Ishizaki K, Tokusashi Y, (1999) Beta-catenin mutations are frequent in hepatocellular carcinomas but absent in adenomas induced by diethylnitrosamine in B6C3F1 mice. Cancer Res 59: 1830-1833.
17. Diwan BA, Meier H, (1976) Carcinogenic effects of a single dose of diethylnitrosamine in three unrelated strains of mice: genetic dependence of the induced tumor types and incidence. Cancer Lett 1: 249-253.
18. Goldfarb S, Pugh TD, Koen H, He YZ, (1983) Preneoplastic and neoplastic progression during hepatocarcinogenesis in mice injected with diethylnitrosamine in infancy. Environ Health Perspect 50: 149-161.
19. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM, (2007) Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27: 55-76.
20. Monga SP, (2011) Role of Wnt/beta-catenin signaling in liver metabolism and cancer. Int J Biochem Cell Biol 43: 1021-1029.
21. Cadoret A, Ovejero C, Saadi-Kheddouci S, Souil E, Fabre M, et al. (2001) Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin. Cancer Res 61: 3245-3249.
22. Harada N, Miyoshi H, Murai N, Oshima H, Tamai Y, et al. (2002) Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin. Cancer Res 62: 1971-1977.
23. Nejak-Bowen KN, Thompson MD, Singh S, Bowen WC Jr, Dar MJ, et al. (2010) Accelerated liver regeneration and hepatocarcinogenesis in mice overexpressing serine-45 mutant beta-catenin. Hepatology 51: 1603-1613.
24. Tan X, Apte U, Micsenyi A, Kotsagrelos E, Luo JH, et al. (2005) Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liver. Gastroenterology 129: 285-302.
25. Harada N, Oshima H, Katoh M, Tamai Y, Oshima M, et al. (2004) Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations. Cancer Res 64: 48-54.
26. Miyoshi H, Deguchi A, Nakau M, Kojima Y, Mori A, et al. (2009) Hepatocellular carcinoma development induced by conditional beta-catenin activation in Lkb1+/- mice. Cancer Sci 100: 2046-2053.
27. Zhang XF, Tan X, Zeng G, Misse A, Singh S, et al. (2011) Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor alpha/phosphoinositide 3-kinase signaling. Hepatology 52: 954-965.
28. Rignall B, Braeuning A, Buchmann A, Schwarz M, (2011) Tumor formation in liver of conditional beta-catenin-deficient mice exposed to a diethylnitrosamine/phenobarbital tumor promotion regimen. Carcinogenesis 32: 52-57.
29. Farazi PA, DePinho RA, (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6: 674-687.
30. Lehwald N, Tao GZ, Jang KY, Sorkin M, Knoefel WT, et al. (2011) Wnt-beta-catenin signaling protects against hepatic ischemia and reperfusion injury in mice. Gastroenterology 141: 707-718, 718 e701-705.
31. Liu S, Yeh TH, Singh VP, Shiva S, Krauland L, et al. (2011) beta-catenin is essential for ethanol metabolism and protection against alcohol-mediated liver steatosis in mice. Hepatology.
32. Nejak-Bowen KN, Monga SP, (2011) Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin Cancer Biol 21: 44-58.
33. Campbell JS, Hughes SD, Gilbertson DG, Palmer TE, Holdren MS, et al. (2005) Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci U S A 102: 3389-3394.
34. Zeng G, Apte U, Cieply B, Singh S, Monga SP, (2007) siRNA-mediated beta-catenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia 9: 951-959.
35. Heldin CH, Ostman A, Ronnstrand L, (1998) Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta 1378: F79-113.
36. Barone MV, Courtneidge SA, (1995) Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src. Nature 378: 509-512.
37. Wang EY, Yeh SH, Tsai TF, Huang HP, Jeng YM, et al. (2011) Depletion of beta-catenin from mature hepatocytes of mice promotes expansion of hepatic progenitor cells and tumor development. Proc Natl Acad Sci U S A 108: 18384-18389.
38. Sekine S, Ogawa R, Kanai Y, (2011) Hepatomas with activating Ctnnb1 mutations in 'Ctnnb1-deficient' livers: a tricky aspect of a conditional knockout mouse model. Carcinogenesis 32: 622-628.
39. Thompson MD, Wickline ED, Bowen WB, Lu A, Singh S, et al. (2011) Spontaneous repopulation of beta-catenin null livers with beta-catenin-positive hepatocytes after chronic murine liver injury. Hepatology 54: 1333-1343.
40. Behari J, Yeh TH, Krauland L, Otruba W, Cieply B, et al. (2010) Liver-specific beta-catenin knockout mice exhibit defective bile acid and cholesterol homeostasis and increased susceptibility to diet-induced steatohepatitis. Am J Pathol 176: 744-753.
41. Tan X, Behari J, Cieply B, Michalopoulos GK, Monga SP, (2006) Conditional deletion of beta-catenin reveals its role in liver growth and regeneration. Gastroenterology 131: 1561-1572.